Neurodevelopmental Assessment of Infants With Cystic Fibrosis

Neurodevelopmental Assessment Outcomes of Infants With Cystic Fibrosis

Infants included in the study will be divided into two groups as healthy infants and cystic fibrosis infants . Demographic, natal and postnatal information of the infants will be available from patient files. 12 months infants with cystic fibrosis and healthy infants will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Gross Motor Function Measure. The assessment outcomes of healthy and cystic fibrosis infants will be compared.

Inclusion Criteria:

• having diagnosis of cystic fibrosis
• to be postterm24-36 months old

Exclusion Criteria:

• Having congenital anomalies,
• Having an acute infection,
• Risk of high or low neurological impairment due to perinatal stroke, perinatal asphyxia, intra / peri-ventricular hemorrhage (IVH / PVL), bronchopulmonary dysplasia,
• The baby's family not reluctant to involved in study.